| Similar Articles |
|---|
 |
The Motley Fool
August 24, 2010
Ilan Moscovitz |
Treasury: The Future of Finance and the Economy The Treasury Department answers our questions.   |
The Motley Fool
August 21, 2010
Ilan Moscovitz |
Treasury: Volcker Rule "a Top Priority" The Treasury Department answers our questions about financial reform and more. |
The Motley Fool
August 23, 2010
Ilan Moscovitz |
Treasury on Regulatory Failure and "Too Big to Fail" The Treasury Department answers questions on the new regulations and big banking. Part two of a three-part interview. |
BusinessWeek
July 29, 2010
Woellert & Vekshin |
A Would-Be Watchdog Woos the Opposition Elizabeth Warren reaches out to lobbyists and Republicans. |
Bank Systems & Technology
December 1, 2005
Maria Bruno-Britz |
Check 21 Requirements Are Only Beginning The real legal challenges associated with Check 21 are only beginning to emerge. |
Reason
March 2007
David Weigel |
Bob Barr and the Libertarians A former Republican congressman joins a third party. |
The Motley Fool
February 28, 2007
Brian Lawler |
Barr's Becoming Big Generic drug producer Barr Pharmaceuticals announces its first quarterly earnings numbers after acquiring Pliva. Investors, take note. |
The Motley Fool
August 9, 2007
Brian Orelli |
Acquisition Raises Barr Half a year after acquiring a giant competitor, Barr Pharmaceuticals results appear to be on track to increase year-over-year revenues. |
U.S. Banker
January 2011 |
Hits and Has-Beens Beth Mooney was named incoming CEO and chairman of KeyCorp... Michael Barr stepped down as the Treasury Department's assistant secretary for financial institutions... David Johnson, Fannie Mae's CFO, was set to step down... etc. |
The Motley Fool
June 27, 2006
Stephen D. Simpson |
Barr Bulks Up For Barr Labs, buying Pliva adds manufacturing capabilities, market opportunities, and pipeline candidates. Investors, take note. |
The Motley Fool
February 23, 2007
Rich Duprey |
Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see. |
The Motley Fool
November 8, 2006
Brian Lawler |
Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note. |
The Motley Fool
June 30, 2006
Stephen D. Simpson |
Barr Labs and Pliva: Round 2 The Croatian generic drugmaker is now a hot property, as a previously spurned bidder, Icelandic generics firm Actavis, refuses to let Barr Labs win this battle yet. Investors, take note. |
The Motley Fool
June 25, 2008
Brian Orelli |
An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets. |
Reason
December 2003
Jesse Walker |
Bob Barr, Civil Libertarian Representing the right wing of the ACLU, Barr represents a set of conservatives' growing discomfort with the Bush administration's erosion of individual liberty. |
Reason
November 2008
David Weigel |
Bob Barr Talks The best-known nominee in Libertarian Party history talks to reason about war, drugs, pornography, Bill Clinton, George Bush, and Ayn Rand. |
The Motley Fool
September 11, 2006
Brian Lawler |
Barr's Bidding War Barr Pharmaceuticals takes a big bite of the booming generics market. Investors, take note. |
The Motley Fool
September 19, 2006
Brian Lawler |
Barr's Winning Bid The pharmaceutical wins its tug-of-war for generic drug firm Pliva. Investors would be smart to watch for any potential teething problems from the much larger and busier Barr. |
The Motley Fool
July 16, 2007
Brian Orelli |
Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price. |
The Motley Fool
June 27, 2008
Brian Orelli |
Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out. |
The Motley Fool
August 8, 2008
Rich Duprey |
Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals. |
The Motley Fool
February 29, 2008
Brian Orelli |
Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006. |
The Motley Fool
August 15, 2006
Stephen D. Simpson |
Twirling the Barr Look closely and you'll see that Barr posted a solid quarter. Investors, if you haven't checked this one out yet, now may be the time for a little due diligence. |
The Motley Fool
May 12, 2008
Brian Orelli |
Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations. |
BusinessWeek
January 10, 2005
Mara Der Hovanesian |
Barr: A No-Name Star More than $30 billion in patents will elapse by the end of 2007, which spells new potential for generics such as Barr Pharmaceuticals. With Barr's solid pipeline, the stock, at $46, is a bargain. |
The Motley Fool
November 1, 2005
Stephen D. Simpson |
Belly Up to Barr Though not cheap, this is a high-quality generic drug company. However, investors must do their own due diligence and decide for themselves whether today's price offers enough margin of safety for a sound investment. |
The Motley Fool
September 8, 2005
Stephen D. Simpson |
Raising the Barr This large generics company sees better margins and an optimistic outlook. The company has a top-notch return on assets and a valuation that, while not cheap, isn't ridiculous either. |
